PTGS2 and depressive disorder: In the current study, we performed a comparative analysis between the prototypic SSCI, LM-4131, and two traditional COX-2 inhibitors currently or previously approved for pain and arthritis, Lumiracoxib (LMX) and Celecoxib, in a variety of measures of mouse anxiety-, fear- and depression-related behavior.